gene is virtually undetectable in the thymus.
Figure 1. A Regulatory Model for B Cell Development
The E2A gene encodes two basic helix-loop-helix vitro in the presence of stromal cells and IL-7. They express wild-type levels of PU.1, Ikaros, E2A, and EBF (bHLH) proteins, E12 and E47, which are generated by alternative splicing. Both proteins act in concert to protranscripts. Furthermore, expression of Rag1, Rag2, and the surrogate light chain genes is unimpaired. However, mote B cell development (Bain et al., 1997) . Very few B220 ϩ B cell progenitors are generated in E2A Ϫ/Ϫ mice. Pax5 mutant pro-B cells express low levels of mb-1 and do not induce CD19 expression. Pax5 directly regulates Such cells are blocked for Ig heavy chain gene rearrangement and fail to express Rag1, mb-1, 5, and transcription of these two B cell-specific genes (Nutt et al., 1998) . Finally, Pax5 mutant pro-B cells are selec-CD19 transcripts. C. Murre described ectopic, gain-offunction experiments with the E12 gene product that tively impaired for V to DJ recombination at the IgH locus, a phenotype that is also associated with the ILsuggested that E2A regulates EBF expression (Kee and Murre, 1998). He showed that conversion of the pre-B 7R mutation (Corcoran et al., 1998) T lineage cells. These functions would include represfactors may also promote or impede tumorigenesis by sion of lineage-inappropriate genes and setting threshother mechanisms as exemplified by the anti-oncoolds for lymphocyte activation. Considerable progress genes or "tumor suppressors" p53 and Rb. We have is being made in identifying and analyzing regulators mentioned earlier that certain of the factors discussed that function to specify cell fate decisions at various above negatively control signaling threshholds in lymphocytes, leading to hyperproliferation and in some nodal points in the lymphoid system, for example, during
